American Diabetes Association
Browse
Supplemental_appendix (1).pdf (206.52 kB)

'Achieving Normoglycemia with Tirzepatide: Analysis of SURPASS 1-4 trials'

Download (206.52 kB)
figure
posted on 2023-09-05, 20:20 authored by Julio Rosenstock, Luis Vázquez, Stefano Del Prato, Denise Reis Franco, Govinda J. Weerakkody, Biyue Dai, Laura Fernández Landó, Brandon K Bergman, Angel Rodríguez

Objective

Tirzepatide is a novel single-molecule GIP/GLP-1 receptor agonist, that demonstrated unprecedented improvements in glycemic control and body weight loss, in the SURPASS phase 3 program. In this exploratory analysis, we aimed to characterize tirzepatide-treated participants who achieved HbA1c <5.7% and evaluate changes in clinical markers associated with long-term cardiometabolic health.

Research design and methods

Baseline characteristics and change from baseline to Week 40 for several efficacy and safety parameters were analyzed according to HbA1c attainment category (<5.7%, 5.7-6.5% and >6.5%) using descriptive statistics in participants taking ≥75% of treatment doses, without rescue medication, in the SURPASS 1-4 trials (N=3229). Logistic regression models with tirzepatide doses adjusted as a covariate, were used to obtain odds ratios and assess the impact of patient characteristics achieving an HbA1c <5.7%.

Results

Tirzepatide-treated participants who achieved HbA1c <5.7% were slightly younger, with shorter duration of diabetes and lower HbA1c value at baseline compared to those who did not achieve HbA1c <5.7%. In addition, they showed greater improvements in HbA1c, body weight, waist circumference, blood pressure, liver enzymes, and lipid parameters without increasing hypoglycemia risk.

Conclusions

Normoglycemia was unprecedently achieved in a significant proportion of participants in the SURPASS clinical program, without increasing hypoglycemia risk, and was associated with an overall improvement in metabolic health.

Funding

Funded by Eli Lilly and Company.

History

Usage metrics

    Diabetes Care

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC